6-<4-(1H-imidazol-1-yl)phenyl>-5-methyl-3(2H)-pyridazinone | 86798-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-<4-(1H-imidazol-1-yl)phenyl>-5-methyl-3(2H)-pyridazinone
• 英文别名: 6-[4-(1H-imidazol-1-yl)phenyl]-5-methyl-3-(2H)pyridazinone；6-[4-(1H-imidazol-1-yl)phenyl]-5-methyl-3(2H)-pyridazinone；6-(4-(1H-Imidazol-1-yl)phenyl)-5-methylpyridazin-3(2H)-one；3-(4-imidazol-1-ylphenyl)-4-methyl-1H-pyridazin-6-one
• CAS: 86798-76-7
• 化学式: C₁₄H₁₂N₄O
• 分子量: 252.275
• InChiKey: JHCQIYAUCIHYNU-UHFFFAOYSA-N

物化性质

• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-(4-甲醛基苯基)咪唑 在 盐酸 、 manganese(IV) oxide 、 氢氧化钾 、 对甲苯磺酸 、 一水合肼 、 溶剂黄146 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 丙醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.5h， 生成 6-<4-(1H-imidazol-1-yl)phenyl>-5-methyl-3(2H)-pyridazinone
  参考文献：
  名称：

  强心剂。2. 4,5-二氢-6- [4-（1H-咪唑-1-基）苯基] -3（2H）-哒嗪酮的合成及其构效关系：一类新型的正性变力剂。

  摘要：

  合成了一系列的4,5-二氢-6- [4-（1H-咪唑-1-基）苯基] -3（2H）-哒嗪酮和相关化合物，并评价其正性肌力活性。该系列的大多数成员产生剂量相关的心肌收缩力增加，这与心率相对较小的升高和全身动脉血压的降低有关。在1的5位上引入甲基取代基（CI-914）产生了该系列中最有效的化合物（11，CI-930）。化合物1比氨力农更有效，而化合物11比米力农更有效。1和11的正性肌力作用不是通过刺激β-肾上腺素受体介导的。心脏磷酸二酯酶组分III的选择性抑制代表1和11的正性肌力作用的主要成分。

  DOI：

  10.1021/jm00148a006

文献信息

• Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and
  申请人：Warner-Lambert Company

  公开号：US04734415A1

  公开（公告）日：1988-03-29

  Substituted 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinone compounds and 6-(substituted)phenyl-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic and antihypertensive agents. Said compounds cause a significant increase in myocardial contractility in the dog. Said compounds also cause a decrease in blood pressure in the spontaneously hypertensive rat. Said compounds are produced by reacting substituted .gamma.-oxobenzenebutanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones which are dehydrogenated to 6-(substituted)phenyl-3(2H)-pyridazinones. Both the intermediate 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones and the 6-(substituted)phenyl-3(2H)-pyridazinones are useful as cardiotonic and antihypertensive agents.

  4,5-二氢-6-(取代基)苯基-3(2H)-吡啶并酮化合物和6-(取代基)苯基-3(2H)-吡啶并酮化合物及其药用盐可作为强心和降压药物。这些化合物在狗体内可显著增加心肌收缩力。这些化合物还可导致自发性高血压大鼠的血压降低。这些化合物是通过将取代的γ-氧基苯丁酸与适当取代的肼反应制备的，从而提供4,5-二氢-6-(取代基)苯基-3(2H)-吡啶并酮，然后将其脱氢为6-(取代基)苯基-3(2H)-吡啶并酮。中间体4,5-二氢-6-(取代基)苯基-3(2H)-吡啶并酮和6-(取代基)苯基-3(2H)-吡啶并酮均可作为强心和降压药物。
• Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted)phenyl-3(2H)-pyridazinones
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0075436A1

  公开（公告）日：1983-03-30

  Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinone compounds and 6-(substituted)phenyl-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic and antihypertensive agents. Said compounds cause a significant increase in myocardial contractility in the dog. Said compounds also cause a decrease in blood pressure in the spontaneously hypertensive rat. Said compounds are produced by reacting substituted y-oxobenzene-butanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones which are dehydrogenated to 6-(substituted)phenyl-3(2H)-pyridazinones. Both the 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and the 6-(substituted)-phenyl-3(2H)-pyridazinones are useful as cardiotonic and antihypertensive agents. The compounds have the formula: where represents a double or single bond and A is anyone of five types of heterocyclic ring-containing radicals, and R2, R3 and Y are hydrogen or various substituents.

  取代的 4,5-二氢-6-(取代)苯基-3(2H)-哒嗪酮化合物和 6-(取代)苯基-3(2H)-哒嗪酮化合物及其药学上可接受的盐类可用作强心剂和降压药。 上述化合物可显著增强狗的心肌收缩力。所述化合物还能降低自发性高血压大鼠的血压。所述化合物是通过取代的 y-氧代苯丁酸与适当取代的肼反应生成 4,5-二氢-6-（取代）苯基-3(2H)-哒嗪酮，后者脱氢生成 6-（取代）苯基-3(2H)-哒嗪酮。 4,5-二氢-6-（取代）苯基-3(2H)-哒嗪酮和 6-（取代）苯基-3(2H)-哒嗪酮均可用作强心剂和降压药。这些化合物的化学式如下 其中代表双键或单键，A 是五种含杂环基中的任何一种，R2、R3 和 Y 是氢或各种取代基。
• Substituted 3-mercaptopyridazines, their 3-alkylthio derivatives and processes for their preparation
  申请人：A. Nattermann & Cie. GmbH

  公开号：EP0122419A2

  公开（公告）日：1984-10-24

  The invention relates to new substituted 3-mercaptopyridazines andtheir3-alkylthio derivatives of the formula 1 and processes for their preparation.

  本发明涉及新的取代的 3-巯基哒嗪及其式 1 的 3-烷硫基衍生物，以及它们的制备工艺。 及其制备工艺。
• US4734415A
  申请人：——

  公开号：US4734415A

  公开（公告）日：1988-03-29
• Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents
  作者：Ila Sircar、Bradley L. Duell、George Bobowski、James A. Bristol、Dale B. Evans

  DOI：10.1021/jm00148a006

  日期：1985.10

  substituent at the 5-position of 1 (CI-914) produced the most potent compound in this series (11, CI-930). Compound 1 is more potent than amrinone whereas compound 11 is more potent than milrinone. The inotropic effects of 1 and 11 are not mediated via stimulation of beta-adrenergic receptors. Selective inhibition of cardiac phosphodiesterase fraction III represents the principal component of the positive

  合成了一系列的4,5-二氢-6- [4-（1H-咪唑-1-基）苯基] -3（2H）-哒嗪酮和相关化合物，并评价其正性肌力活性。该系列的大多数成员产生剂量相关的心肌收缩力增加，这与心率相对较小的升高和全身动脉血压的降低有关。在1的5位上引入甲基取代基（CI-914）产生了该系列中最有效的化合物（11，CI-930）。化合物1比氨力农更有效，而化合物11比米力农更有效。1和11的正性肌力作用不是通过刺激β-肾上腺素受体介导的。心脏磷酸二酯酶组分III的选择性抑制代表1和11的正性肌力作用的主要成分。